Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan Griffin

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Diabetes, Obesity & Metabolism|January 10, 2025
Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trialsDomenica M Rubino, Sue D Pedersen, Lisa Connery, et al.
Diabetes, Obesity & Metabolism|November 6, 2023
Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysisEmily R Hankosky, Hui Wang, Lisa M Neff, et al.
Cancers|January 18, 2020
Outcomes of Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs)Katharine Thomas, Brianne A Voros, Meghan Meadows-Taylor, et al.
BMC Geriatrics|March 27, 2024
Tools to measure barriers to medication management capacity in older adults: a scoping reviewBincy Baby, Annette McKinnon, Kirk Patterson, et al.
Mayo Clinic Proceedings. Digital Health|August 29, 2025
Medication Adherence Technologies: A Classification Taxonomy Based on FeaturesBincy Baby, Jasdeep Kaur Gill, Sadaf Faisal, et al.
Diabetes, Obesity & Metabolism|March 8, 2026
Association of Tirzepatide With Kidney Parameters in Participants With Obesity and Prediabetes From SURMOUNT-1 Over 176 WeeksHiddo J L Heerspink, Daniel H van Raalte, Katherine Tuttle, et al.
Journal of the American Society of Nephrology : JASN|June 13, 2025
Kidney Parameters with Tirzepatide in Obesity with or without Type 2 DiabetesHiddo J L Heerspink, Allon N Friedman, Petter Bjornstad, et al.
Nature Medicine|May 12, 2026
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trialLouis J Aronne, Deborah B Horn, Carel W le Roux, et al.
JMIR Aging|April 8, 2026
Personalized Predictive Model to Predict Subtask Success of Medication Adherence Technologies for Older Adults With Diverse Capabilities: Development and Internal Validation StudyBincy Baby, Ghada Elba, Minzee Kim, et al.
BMJ Open|November 11, 2022
Induction of labour for predicted macrosomia: study protocol for the 'Big Baby' randomised controlled trialLauren Jade Ewington, Jason Gardosi, Ranjit Lall, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Diabetes, Obesity & Metabolism|January 10, 2025
Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trialsDomenica M Rubino, Sue D Pedersen, Lisa Connery, et al.
Diabetes, Obesity & Metabolism|November 6, 2023
Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysisEmily R Hankosky, Hui Wang, Lisa M Neff, et al.
Cancers|January 18, 2020
Outcomes of Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs)Katharine Thomas, Brianne A Voros, Meghan Meadows-Taylor, et al.
BMC Geriatrics|March 27, 2024
Tools to measure barriers to medication management capacity in older adults: a scoping reviewBincy Baby, Annette McKinnon, Kirk Patterson, et al.
Mayo Clinic Proceedings. Digital Health|August 29, 2025
Medication Adherence Technologies: A Classification Taxonomy Based on FeaturesBincy Baby, Jasdeep Kaur Gill, Sadaf Faisal, et al.
Diabetes, Obesity & Metabolism|March 8, 2026
Association of Tirzepatide With Kidney Parameters in Participants With Obesity and Prediabetes From SURMOUNT-1 Over 176 WeeksHiddo J L Heerspink, Daniel H van Raalte, Katherine Tuttle, et al.
Journal of the American Society of Nephrology : JASN|June 13, 2025
Kidney Parameters with Tirzepatide in Obesity with or without Type 2 DiabetesHiddo J L Heerspink, Allon N Friedman, Petter Bjornstad, et al.
Nature Medicine|May 12, 2026
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trialLouis J Aronne, Deborah B Horn, Carel W le Roux, et al.
JMIR Aging|April 8, 2026
Personalized Predictive Model to Predict Subtask Success of Medication Adherence Technologies for Older Adults With Diverse Capabilities: Development and Internal Validation StudyBincy Baby, Ghada Elba, Minzee Kim, et al.
BMJ Open|November 11, 2022
Induction of labour for predicted macrosomia: study protocol for the 'Big Baby' randomised controlled trialLauren Jade Ewington, Jason Gardosi, Ranjit Lall, et al.
Pageof 2